Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed / Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

Inclusion Criteria

• Inclusion Criteria: -- Age ≥18 years - Histologically confirmed Follicular Lymphoma (Grade 1, 2 or 3a), Marginal Zone Lymphoma, or Mantle Cell Lymphoma - Must have documented relapsed, refractory or Progressive Disease after last treatment with systemic therapy - Bi-dimensionally measurable disease - Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2 - Adequate bone marrow function - Willingness to follow pregnancy precautions Exclusion Criteria: - Histology other than follicular or marginal zone lymphoma or clinical evidence of transformation or Grade 3b follicular lymphoma - Any medical condition (other than the underlying lymphoma) that requires chronic steroid use - Subjects taking corticosteroids during the last 1 week prior treatment, unless administered at a dose equivalent to < 20 mg/day of prednisone - Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8 weeks use of radioimmunotherapy within 3 months - Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) - Known sensitivity or allergy to murine products - Presence or history of central nervous system involvement by lymphoma. Subjects who are at a risk for a thromboembolic event and are not willing to take prophylaxis for it. - Any condition that places the subject at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.

MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades

1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell

lymphoma (MCL) who received ≥1 prior therapy and had stage I-IV, measurable disease. ~500

patients are planned for enrollment in 12 cycles of R2 induction, with a projected ~314

patients with ≥SD after induction randomized (1:1) to two maintenance arms. Induction

includes oral lenalidomide 20 mg/day, days 1-21 per 28-day cycle (d1-21/28) plus IV rituximab

375 mg/m2, days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 3, 5, 7, 9, and 11 (28-day

cycles). Patients are then randomized to maintenance lenalidomide 10 mg/day, d1-21/28, cycles

13-30, plus rituximab 375 mg/m2, day 1 of cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 (R2,

Arm A), or rituximab alone (same schedule, Arm B). Patients receiving R2 maintenance after 18

cycles may continue maintenance lenalidomide monotherapy 10 mg/day, d1-21/28 (per patient

and/or investigator discretion), until disease progression as tolerated. The primary endpoint

is progression-free survival (per modified 1999 IWG criteria). Secondary endpoints include

safety, overall survival, response rates, duration of response, and quality of life

(exploratory). Patients will be followed for ≥5 years after the last patient initiated

induction therapy. Enrollment in MAGNIFY began in March 2014; as of Jan 2016, 133 patients

are enrolled.

Trial Phase Phase III

Trial Type Treatment

Lead Organization
Celgene Corporation

• Primary ID CC-5013-NHL-008
• Secondary IDs NCI-2015-00708
• Clinicaltrials.gov ID NCT01996865